Opinion|Videos|January 3, 2025
Recommended Guidelines for Cervical Cancer Screening
Author(s)Kameelah Phillips, MD, FACOG, NCMP
Kameelah Phillips, MD, FACOG, NCMP, discusses how cervical cancer remains a significant health concern, emphasizing current incidence and prevalence rates, the critical importance of regular screenings in early detection and prevention, and the recommended guidelines for cervical cancer screening during well-woman visits.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please provide an overview of cervical cancer.
- What is the current cervical cancer incidence and prevalence?
- Please discuss the importance of regular screenings.
- What are the recommended guidelines for cervical cancer screening during a well-woman visit?
Advertisement
Related to this article
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
FDA removes boxed warnings from 3 more menopausal hormone therapy products
3
Matthew Nudy, MD, on estrogen and the cardiovascular system
4
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
5